Low grade serous ovarian cancer: Unpicking drivers of outcome
Authors:
- 29 October 2022
- journal article
- editorial
- Published by Elsevier in Gynecologic Oncology
- Vol. 167 (2) , 137-138
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survivalGynecologic Oncology, 2022
- NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022Journal of the National Comprehensive Cancer Network, 2022
- Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expressionnpj Precision Oncology, 2022
- MAPK Pathway Genetic Alterations Are Associated with Prolonged Overall Survival in Low-Grade Serous Ovarian CarcinomaClinical Cancer Research, 2022
- The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomesGynecologic Oncology, 2022
- Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trialThe Lancet, 2022
- MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary PeritoneumJournal of Clinical Oncology, 2020
- Genomic analysis of low‐grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilitiesThe Journal of Pathology, 2020
- Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?Gynecologic Oncology, 2017
- Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or PeritoneumJournal of Clinical Oncology, 2017